Abstract

BackgroundTraditionally, mutational burden and mutational signatures have been assessed by tumor-normal pair DNA sequencing. The requirement of having both normal and tumor samples is not always feasible from a clinical perspective, and led us to investigate the efficacy of using RNA sequencing of only the tumor sample to determine the mutational burden and signatures, and subsequently molecular cause of the cancer. The potential advantages include reducing the cost of testing, and simultaneously providing information on the gene expression profile and gene fusions present in the tumor.ResultsIn this study, we devised supervised and unsupervised learning methods to determine mutational signatures from tumor RNA-seq data. As applications, we applied the methods to a training set of 587 TCGA uterine cancer RNA-seq samples, and examined in an independent testing set of 521 TCGA colorectal cancer RNA-seq samples. Both diseases are known associated with microsatellite instable high (MSI-H) and driver defects in DNA polymerase ɛ (POLɛ). From RNA-seq called variants, we found majority (> 95%) are likely germline variants, leading to C > T enriched germline variants (dbSNP) widely applicable in tumor and normal RNA-seq samples. We found significant associations between RNA-derived mutational burdens and MSI/POLɛ status, and insignificant relationship between RNA-seq total coverage and derived mutational burdens. Additionally we found that over 80% of variants could be explained by using the COSMIC mutational signature-5, -6 and -10, which are implicated in natural aging, MSI-H, and POLɛ, respectively. For classifying tumor type, within UCEC we achieved a recall of 0.56 and 0.78, and specificity of 0.66 and 0.99 for MSI and POLɛ respectively. By applying learnt RNA signatures from UCEC to COAD, we were able to improve our classification of both MSI and POLɛ.ConclusionsTaken together, our work provides a novel method to detect RNA-seq derived mutational signatures with effective procedures to remove likely germline variants. It can leads to accurate classification of underlying driving mechanisms of DNA damage deficiency.

Highlights

  • Mutational burden and mutational signatures have been assessed by tumor-normal pair DNA sequencing

  • Tumors that display high levels of genetic diversity are often susceptible to PD-L1 inhibitors as variants in the DNA sequences lead to the Jessen et al BMC Med Genomics (2021) 14:65 display of abnormal proteins on the tumor cell surface, allowing the immune system to attack the tumor in the absence of the PD-1/PD-L1 “off switch” [3]

  • We investigated the efficacy of microsatellite instable high (MSI-H) and polymerase ɛ (POLɛ) classification from RNA -sequencing, using only a tumor sample without its corresponding normal sample

Read more

Summary

Introduction

Mutational burden and mutational signatures have been assessed by tumor-normal pair DNA sequencing. The requirement of having both normal and tumor samples is not always feasible from a clinical perspective, and led us to investigate the efficacy of using RNA sequencing of only the tumor sample to determine the mutational burden and signatures, and subsequently molecular cause of the cancer. Tumors that display high levels of genetic diversity are often susceptible to PD-L1 inhibitors as variants in the DNA sequences lead to the Jessen et al BMC Med Genomics (2021) 14:65 display of abnormal proteins on the tumor cell surface, allowing the immune system to attack the tumor in the absence of the PD-1/PD-L1 “off switch” [3]. Different tumor types display highly different levels of mutational burden and high TMB is associated with response to immunotherapies [4]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.